|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 9/00 | |
| A61K 9/16 | |||
| A61K 31/712 | |||
| C07K 16/22 | |||
| A61P 27/02 |
| (11) | Number of the document | 2664347 |
| (13) | Kind of document | T |
| (96) | European patent application number | 13179231.9 |
| Date of filing the European patent application | 2009-07-13 | |
| (97) | Date of publication of the European application | 2013-11-20 |
| (45) | Date of publication and mention of the grant of the patent | 2019-03-13 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 176238 | 2008-07-18 | US |
| (72) |
Robinson, Michael R., US
Blanda, Wendy M., US
Hughes, Patrick M., US
Burke, A. James, US
Whitcup, Scott M., US
|
| (73) |
ALLERGAN, INC.,
2525 Dupont Drive, Irvine, CA 92612,
US
|
| (54) | Bevacizumab for use in a method for treating atrophic age related macular degeneration |
| Bevacizumab for use in a method for treating atrophic age related macular degeneration |